Display options
Cite
Olsen RJ, Tarantolo SR, Hinrichs SH. Molecular approaches to sarcoma therapy. Sarcoma. 2002;6(1):27-42doi: 10.1080/13577140220127530.
Olsen, R. J., Tarantolo, S. R., & Hinrichs, S. H. (2002). Molecular approaches to sarcoma therapy. Sarcoma, 6(1), 27-42. https://doi.org/10.1080/13577140220127530
Olsen, R J, et al. "Molecular approaches to sarcoma therapy." Sarcoma vol. 6,1 (2002): 27-42. doi: https://doi.org/10.1080/13577140220127530
Olsen RJ, Tarantolo SR, Hinrichs SH. Molecular approaches to sarcoma therapy. Sarcoma. 2002;6(1):27-42. doi: 10.1080/13577140220127530. PMID: 18521343; PMCID: PMC2395489.
Copy Download .nbib Format: NLM
Share it on

Sarcoma. 2002;6(1):27-42. doi: 10.1080/13577140220127530.

Molecular approaches to sarcoma therapy.

Sarcoma

R J Olsen, S R Tarantolo, S H Hinrichs

Affiliations

  1. Department of Pathology and Microbiology University of Nebraska Medical Center Omaha NE 69198-6495 USA.

PMID: 18521343 PMCID: PMC2395489 DOI: 10.1080/13577140220127530

Abstract

Soft tissue sarcomas comprise a heterogeneous group of aggressive tumors that have a relatively poor prognosis. Although conventional therapeutic regimens can effectively cytoreduce the overall tumor mass, they fail to consistently achieve a curative outcome. Alternative gene-based approaches that counteract the underlying neoplastic process by eliminating the clonal aberrations that potentiate malignant behavior have been proposed. As compared to the accumulation of gene alterations associated with epithelial carcinomas, sarcomas are frequently characterized by the unique presence of a single chromosomal translocation in each histological subtype. Similar to the Philadelphia chromosome associated with CML, these clonal abnormalities result in the fusion of two independent unrelated genes to generate a unique chimeric protein that displays aberrant activity believed to initiate cellular transformation. Secondary gene mutations may provide an additional growth advantage that further contributes to malignant progression. The recent clinical success of the tyrosine kinase inhibitor, STI571, suggests that therapeutic approaches specifically directed against essential survival factors in sarcoma cells may be effective. This review summarizes published approaches targeting a specific molecular mechanism associated with sarcomagenesis. The strategy and significance of published translational studies in six distinct areas are presented. These include: (1) the disruption of chimeric transcription factor activity; (2) inhibition of growth stimulatory post-translational modifications; (3) restoration of tumor suppressor function; (4) interference with angiogenesis; (5) induction of apoptotic pathways; and (6) introduction of toxic gene products. The potential for improving outcomes in sarcoma patients and the conceptual obstacles to be overcome are discussed.

References

  1. N Engl J Med. 2001 Apr 5;344(14):1084-6 - PubMed
  2. Nature. 1998 Jan 1;391(6662):86-9 - PubMed
  3. Adv Drug Deliv Rev. 2000 Nov 15;44(2-3):153-66 - PubMed
  4. Science. 1998 Jan 23;279(5350):577-80 - PubMed
  5. J Clin Oncol. 1996 Apr;14(4):1245-51 - PubMed
  6. Oncol Res. 1998;10(11-12):541-50 - PubMed
  7. J Clin Oncol. 1996 May;14(5):1679-89 - PubMed
  8. Cancer Genet Cytogenet. 1991 Mar;52(1):101-6 - PubMed
  9. Br J Cancer. 1995 Aug;72(2):469-75 - PubMed
  10. Cancer Res. 1992 Jun 15;52(12):3402-8 - PubMed
  11. Cancer. 2000 Aug 15;89(4):793-9 - PubMed
  12. Br J Haematol. 1999 Jun;105(3):690-5 - PubMed
  13. Cell Growth Differ. 1996 Apr;7(4):429-37 - PubMed
  14. Oncology. 1994 Jan-Feb;51(1):13-7 - PubMed
  15. Cancer Lett. 2000 Jul 3;155(1):71-7 - PubMed
  16. Nature. 1975 Aug 7;256(5517):495-7 - PubMed
  17. Cancer Genet Cytogenet. 1994 Dec;78(2):165-71 - PubMed
  18. Blood. 1998 Sep 15;92(6):1927-32 - PubMed
  19. Cell. 1995 Jan 27;80(2):225-36 - PubMed
  20. Cell. 1994 Dec 30;79(7):1157-64 - PubMed
  21. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5752-6 - PubMed
  22. Exp Cell Res. 1999 Jan 10;246(1):38-46 - PubMed
  23. Cancer Gene Ther. 2000 Apr;7(4):574-80 - PubMed
  24. Cancer Res. 1992 Nov 15;52(22):6194-9 - PubMed
  25. Cancer Res. 2000 Jul 1;60(13):3655-61 - PubMed
  26. Oncogene. 2000 Aug 10;19(34):3878-87 - PubMed
  27. J Neurooncol. 1997 Jan;31(1-2):9-16 - PubMed
  28. Cancer Res. 2000 Nov 1;60(21):6160-70 - PubMed
  29. N Engl J Med. 1995 May 4;332(18):1181-5 - PubMed
  30. Cell. 1991 Jul 26;66(2):233-43 - PubMed
  31. Int J Biochem Cell Biol. 1998 Jan;30(1):27-38 - PubMed
  32. Clin Cancer Res. 1998 Aug;4(8):1985-94 - PubMed
  33. J Clin Oncol. 1998 Apr;16(4):1248-55 - PubMed
  34. Semin Surg Oncol. 1999 Jul-Aug;17(1):78-82 - PubMed
  35. Zhonghua Zhong Liu Za Zhi. 1998 Jul;20(4):280-3 - PubMed
  36. Science. 1995 Mar 10;267(5203):1449-56 - PubMed
  37. Cancer Gene Ther. 2000 Mar;7(3):422-9 - PubMed
  38. Cytokine Growth Factor Rev. 1996 Dec;7(4):311-25 - PubMed
  39. Br J Cancer. 1996 Feb;73(4):472-6 - PubMed
  40. Am J Pathol. 1994 Aug;145(2):345-55 - PubMed
  41. Curr Probl Surg. 1996 Oct;33(10):817-72 - PubMed
  42. Am J Dermatopathol. 1999 Aug;21(4):392-4 - PubMed
  43. Head Neck. 2000 Aug;22(5):483-8 - PubMed
  44. Cancer Lett. 1996 Feb 27;100(1-2):63-9 - PubMed
  45. Forum (Genova). 1998 Oct-Dec;8(4):368-76 - PubMed
  46. Cancer Res. 1996 Sep 15;56(18):4164-70 - PubMed
  47. Am J Clin Pathol. 1990 Jan;93(1):26-31 - PubMed
  48. Clin Cancer Res. 1999 Oct;5(10):2963-70 - PubMed
  49. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):9901-5 - PubMed
  50. Cancer Gene Ther. 2000 May;7(5):789-98 - PubMed
  51. Cancer. 1996 Feb 15;77(4):675-82 - PubMed
  52. Nature. 1993 Jun 17;363(6430):640-4 - PubMed
  53. Physiol Genomics. 1999 Nov 11;1(3):127-38 - PubMed
  54. Oncologist. 2000;5 Suppl 1:51-4 - PubMed
  55. Cancer Res. 1998 Jan 1;58(1):20-2 - PubMed
  56. Cancer Lett. 2001 Jan;162 Suppl:S23-S32 - PubMed
  57. Cell. 1992 Aug 7;70(3):375-87 - PubMed
  58. Am J Surg Pathol. 2000 Aug;24(8):1097-104 - PubMed
  59. Curr Opin Oncol. 1998 Jul;10(4):318-25 - PubMed
  60. Mol Cell Biol. 1996 May;16(5):2445-52 - PubMed
  61. Sarcoma. 1998;2(1):3-17 - PubMed
  62. J Mol Biol. 2001 Feb 2;305(5):989-1010 - PubMed
  63. Cancer Res. 2000 Mar 15;60(6):1742-9 - PubMed
  64. Mol Med. 1998 Jun;4(6):365-72 - PubMed
  65. Am J Surg Pathol. 1998 Aug;22(8):1026-32 - PubMed
  66. Clin Cancer Res. 2000 Dec;6(12):4848-58 - PubMed
  67. EXS. 1997;79:1-8 - PubMed
  68. Somat Cell Mol Genet. 1998 Sep;24(5):281-9 - PubMed
  69. Clin Chem. 1999 Jan;45(1):7-17 - PubMed
  70. Semin Surg Oncol. 1999 Jul-Aug;17(1):72-7 - PubMed
  71. Eur J Cancer. 2001 Jun;37(9):1096-103 - PubMed
  72. J Immunol. 1997 Sep 1;159(5):2250-8 - PubMed
  73. Surgery. 1999 Aug;126(2):399-405 - PubMed
  74. Semin Surg Oncol. 1999 Jul-Aug;17(1):11-22 - PubMed
  75. Pathol Int. 2000 Sep;50(9):731-8 - PubMed
  76. Cell. 1990 Jun 1;61(5):759-67 - PubMed
  77. Science. 1996 Nov 1;274(5288):784-7 - PubMed
  78. Cancer Res. 2000 Dec 15;60(24):6964-71 - PubMed
  79. Cancer Res. 2000 Mar 1;60(5):1326-31 - PubMed
  80. Curr Opin Oncol. 1996 Jul;8(4):284-8 - PubMed
  81. Cancer Res. 2000 Aug 15;60(16):4311-4 - PubMed
  82. J Biol Chem. 1999 Dec 3;274(49):34811-8 - PubMed
  83. Ann Diagn Pathol. 1998 Dec;2(6):401-21 - PubMed
  84. Diagn Mol Pathol. 2000 Mar;9(1):9-13 - PubMed
  85. J Biol Chem. 1998 Jul 3;273(27):16874-9 - PubMed
  86. J Clin Invest. 1997 Jan 15;99(2):239-47 - PubMed
  87. Mol Ther. 2000 Jan;1(1):71-81 - PubMed
  88. N Engl J Med. 1997 Oct 9;337(15):1021-8 - PubMed
  89. Anticancer Res. 2000 May-Jun;20(3B):2137-43 - PubMed
  90. Oncogene. 2001 Mar 29;20(14):1756-64 - PubMed
  91. Nucleic Acids Res. 1997 Jan 1;25(1):151-7 - PubMed
  92. Ann Surg. 1996 Dec;224(6):756-64; discussion 764-5 - PubMed
  93. Cancer Treat Rev. 2000 Jun;26(3):191-204 - PubMed
  94. Gene. 1999 Sep 17;237(2):281-302 - PubMed
  95. Am J Pathol. 1997 Sep;151(3):735-44 - PubMed
  96. Int J Cancer. 2000 Oct 15;88(2):252-9 - PubMed
  97. Curr Opin Oncol. 1999 Jul;11(4):275-84 - PubMed
  98. Int J Cancer. 2001 May 1;92(3):354-60 - PubMed
  99. Cancer Res. 1999 Apr 1;59(7):1428-32 - PubMed
  100. Nat Med. 1995 Jan;1(1):27-31 - PubMed
  101. Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12547-52 - PubMed
  102. Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14701-6 - PubMed
  103. Sarcoma. 1998;2(2):77-87 - PubMed
  104. Oncogene. 1997 Mar 20;14(11):1259-68 - PubMed
  105. Mol Ther. 2000 Jun;1(6):555-65 - PubMed
  106. Hum Pathol. 2000 May;31(5):532-8 - PubMed
  107. Oncology (Williston Park). 1999 Oct;13(10 Suppl 5):148-54 - PubMed
  108. J Clin Oncol. 2000 Jan;18(1):204-13 - PubMed
  109. Nature. 1989 Oct 12;341(6242):544-6 - PubMed
  110. Int J Oncol. 1999 Dec;15(6):1125-31 - PubMed
  111. Nature. 2000 Sep 14;407(6801):242-8 - PubMed
  112. Scand J Immunol. 1990 Jan;31(1):1-13 - PubMed
  113. Cancer Res. 1998 Sep 15;58(18):4185-92 - PubMed
  114. Blood. 2000 Jan 1;95(1):90-5 - PubMed
  115. Curr Opin Mol Ther. 2000 Dec;2(6):691-6 - PubMed
  116. Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8490-4 - PubMed
  117. Hum Gene Ther. 1996 Aug 1;7(12):1465-82 - PubMed
  118. Clin Cancer Res. 2000 Aug;6(8):3056-61 - PubMed
  119. N Engl J Med. 1971 Nov 18;285(21):1182-6 - PubMed
  120. Mol Cell Biol. 2000 Jul;20(14):5019-31 - PubMed
  121. J Clin Oncol. 1996 Mar;14(3):859-68 - PubMed
  122. Cancer Res. 1999 Nov 15;59(22):5745-50 - PubMed
  123. J Cancer Res Clin Oncol. 1998;124(10):532-40 - PubMed
  124. Oncogene. 1995 May 4;10(9):1749-56 - PubMed
  125. Mol Ther. 2000 May;1(5 Pt 1):457-63 - PubMed
  126. Oncogene. 1999 Dec 13;18(53):7681-9 - PubMed
  127. Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13164-9 - PubMed
  128. Pediatr Hematol Oncol. 1999 Nov-Dec;16(6):539-44 - PubMed
  129. Mol Pathol. 2000 Apr;53(2):55-63 - PubMed
  130. Nature. 1989 Nov 2;342(6245):99-100 - PubMed
  131. N Engl J Med. 1998 Jan 15;338(3):153-60 - PubMed
  132. Cancer Res. 2001 Mar 15;61(6):2641-8 - PubMed
  133. J Orthop Sci. 2000;5(4):418-23 - PubMed
  134. Oncogene. 1997 Dec 4;15(23):2855-66 - PubMed
  135. J Natl Cancer Inst. 1993 Jan 20;85(2):152-7 - PubMed
  136. Oncogene. 1995 Sep 21;11(6):1049-54 - PubMed
  137. Cancer Res. 2000 Sep 15;60(18):5134-42 - PubMed
  138. Cancer Res. 2000 Sep 15;60(18):5117-24 - PubMed
  139. Cancer Lett. 2000 Feb 28;149(1-2):181-8 - PubMed
  140. J Immunol. 1997 Mar 15;158(6):2543-50 - PubMed
  141. Hum Gene Ther. 1999 Sep 20;10(14):2325-35 - PubMed
  142. Clin Cancer Res. 1996 Aug;2(8):1391-5 - PubMed
  143. Cancer Res. 1999 Jul 1;59(13):3100-6 - PubMed
  144. N Engl J Med. 2001 Mar 15;344(11):841-2 - PubMed
  145. Clin Orthop Relat Res. 1995 Jan;(310):176-87 - PubMed
  146. Blood. 2000 Oct 1;96(7):2419-25 - PubMed
  147. Am J Pathol. 1998 Dec;153(6):1937-45 - PubMed
  148. JAMA. 2000 Jan 19;283(3):317, 321 - PubMed
  149. Oncogene. 1999 Jan 14;18(2):551-7 - PubMed
  150. Clin Orthop Relat Res. 2000 Apr;(373):25-31 - PubMed
  151. Ann Intern Med. 1969 Oct;71(4):747-52 - PubMed
  152. N Engl J Med. 2001 Apr 5;344(14):1052-6 - PubMed
  153. Cancer. 2000 Aug 15;89(4):783-92 - PubMed
  154. Nat Genet. 1994 Aug;7(4):502-8 - PubMed
  155. Biochem Biophys Res Commun. 2000 Dec 20;279(2):401-6 - PubMed
  156. J Clin Oncol. 1996 Mar;14(3):869-77 - PubMed
  157. Curr Opin Oncol. 1999 Jul;11(4):267-74 - PubMed
  158. Oncogene. 1995 Feb 2;10(3):423-31 - PubMed
  159. Cancer Res. 2000 Sep 1;60(17):4873-80 - PubMed
  160. Nature. 2000 Sep 14;407(6801):249-57 - PubMed
  161. Semin Cancer Biol. 1999 Aug;9(4):303-18 - PubMed
  162. Semin Surg Oncol. 1999 Jul-Aug;17(1):47-51 - PubMed
  163. Cancer Res. 1988 Aug 15;48(16):4597-603 - PubMed
  164. Semin Diagn Pathol. 2000 Aug;17(3):194-203 - PubMed
  165. Semin Cancer Biol. 1997 Apr;8(2):113-9 - PubMed
  166. Cancer Lett. 1999 May 24;139(2):159-65 - PubMed
  167. Cancer Res. 1996 Oct 15;56(20):4614-9 - PubMed
  168. Br J Cancer. 1995 Oct;72(4):986-91 - PubMed
  169. J Biol Chem. 1996 Apr 5;271(14):8008-14 - PubMed
  170. Science. 1994 Dec 16;266(5192):1865-9 - PubMed
  171. Cancer Res. 1998 Dec 15;58(24):5842-9 - PubMed
  172. Anticancer Drug Des. 2000 Feb;15(1):67-72 - PubMed
  173. Clin Cancer Res. 1998 Jan;4(1):145-52 - PubMed
  174. Med Pediatr Oncol. 1999 Dec;33(6):530-5 - PubMed

Publication Types